Although GPCR-mediated EGFR transactivation was identified as a crucial mechanism in modulating a variety of tumor cell signaling and functions (Köse, 2017), therapeutic potentials of GPCRs have been rarely probed in EGFR-TKI resistance. Here, EGFR is linked to neoplasm.